$277.8 M

TCRR Mkt cap, 27-May-2020
TCR2 Therapeutics Net income (Q1, 2020)-15.5 M
TCR2 Therapeutics EBIT (Q1, 2020)-16.2 M
TCR2 Therapeutics Cash, 31-Mar-202031.1 M

TCR2 Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2019

R&D expense

7.7m9.6m37.5m

General and administrative expense

2.3m3.6m13.9m

Operating expense total

9.9m13.2m51.4m

EBIT

(9.9m)(13.1m)(51.4m)

Pre tax profit

(47.5m)

Income tax expense

102.0k

Net Income

(9.9m)(13.1m)(47.6m)

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

R&D expense

7.9m8.8m11.4m12.0m

General and administrative expense

2.9m3.3m3.5m4.3m

Operating expense total

10.8m12.1m14.9m16.2m

EBIT

(10.8m)(12.1m)(14.9m)(16.2m)

Interest expense

872.0k1.1m1.1m

Pre tax profit

(15.5m)

Income tax expense

27.0k

Net Income

(9.9m)(11.1m)(13.8m)(15.5m)

TCR2 Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2019

Cash

8.0m19.8m65.3m

Prepaid Expenses

975.0k892.0k5.1m

Current Assets

17.3m20.7m163.2m

PP&E

936.0k1.0m4.9m

Total Assets

18.3m22.0m168.5m

Accounts Payable

508.0k427.0k2.5m

Current Liabilities

966.0k1.2m7.5m

Total Liabilities

966.0k1.3m8.1m

Common Stock

2.0k

Preferred Stock

29.2m47.1m

Additional Paid-in Capital

342.9m

Retained Earnings

(11.9m)(26.3m)(182.6m)

Total Equity

17.3m20.8m160.4m

Financial Leverage

1.1 x1.1 x1.1 x

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

46.4m41.0m49.3m31.1m

Prepaid Expenses

3.9m6.1m5.6m6.8m

Current Assets

165.6m175.7m166.6m133.0m

PP&E

1.9m3.2m4.5m5.2m

Total Assets

197.9m190.3m179.5m153.3m

Accounts Payable

2.8m4.0m3.6m3.2m

Current Liabilities

5.4m7.2m7.9m6.1m

Total Liabilities

5.8m7.6m8.4m6.7m

Common Stock

2.0k2.0k2.0k2.0k

Additional Paid-in Capital

336.9m338.4m340.7m345.1m

Retained Earnings

(144.9m)(156.0m)(169.8m)(198.1m)

Total Equity

192.0m182.6m171.2m146.6m

Financial Leverage

1 x1 x1 x1 x

TCR2 Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2019

Net Income

(9.9m)(13.1m)(47.6m)

Depreciation and Amortization

220.0k298.0k862.0k

Accounts Payable

76.0k(101.0k)(179.0k)

Cash From Operating Activities

(9.4m)(12.0m)(41.4m)

Purchases of PP&E

(8.3m)(6.5m)(3.9m)

Cash From Investing Activities

(9.2m)7.7m(20.4m)

Cash From Financing Activities

22.5m16.2m79.5m

Net Change in Cash

3.9m11.8m17.7m

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(9.9m)(21.0m)(34.8m)(15.5m)

Depreciation and Amortization

135.0k300.0k558.0k306.0k

Accounts Payable

(401.0k)180.0k489.0k603.0k

Cash From Operating Activities

(10.8m)(21.0m)(31.0m)(16.4m)

Purchases of PP&E

(188.0k)(941.0k)(3.1m)(504.0k)

Cash From Investing Activities

(70.0m)(64.9m)(46.6m)(17.8m)

Cash From Financing Activities

79.6m79.2m79.4m50.0k

Net Change in Cash

(1.3m)(6.7m)1.8m(34.2m)

TCR2 Therapeutics Ratios

USDY, 2020

Financial Leverage

1 x